#HIV #Healthcare #ClinicalTrials
www.yahoo.com
ViiV's four-monthly HIV drug maintains viral suppression at 12 months
Add Yahoo as a preferred source to see more of our stories on Google.
ViiV Healthcare's investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial.
#VisionRestoration #EyeHealth #ClinicalTrials
www.forbes.com
A New Era For Blindness Treatment Is Within Sight
Seeing is believing. For patients in clinical trials for eye diseases, that truism is literal.
From stem cells to bionic vision implants, there's never been a more exciting time for novel approaches to treating devastating eye conditions.
#glioblastoma #brainhealth #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
#glioblastoma #cancerresearch #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
U
#ADHD #ClinicalTrials #MentalHealth
www.usnews.com
FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes
By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 20, 2026 (HealthDay News) -- A U. S. Food and Drug Administration (FDA)-approved device for treating ADHD in kids simply doesn't work, a new clinical trial says.
#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Neuroscience #Alzheimers #ClinicalTrials
www.nasdaq.com
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) has entered 2026 with momentum, announcing positive Phase 1b results for its lead candidate NMRA-511 in Alzheimer's disease agitation, along with a pipeline strategy that promises multiple clinical readouts across its neuroscience programs.
#NeumoraTherapeutics #Alzheimers #ClinicalTrials
www.nasdaq.com
Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) on Monday announced positive results from a Phase 1b study of NMRA-511 in patients with agitation associated with Alzheimer's disease (AD).
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
